West Pharmaceutical Services, Inc. (WST), based in Exton, Pennsylvania, designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas and internationally. With a market cap of $14.8 billion, the company operates in two segments, Proprietary Products and Contract-Manufactured Products.

WST shares have lagged behind the broader market over the past year, declining 37.4% compared to the S&P 500 Index’s ($SPX) 10.2% surge. Moreover, in 2025, the stock has fallen 37.2%, underperforming the SPX’s 1.3% decline.

Narrowing the focus, WST has also trailed the Health Care Select Sector SPDR Fund’s (XLV) 10.1% fall over the past 52 weeks and its 5.3% decline in 2025.

On Apr. 24, WST stock declined 3.5% following the release of its Q1 earnings. The company reported a revenue of $698 million, surpassing the Street’s estimates. WST’s adjusted EPS for the quarter amounted to $1.45 and successfully beat the consensus estimates by 18.9%.

For the current year ending in December, analysts expect WST’s EPS to decline 7% to $6.28 on a diluted basis. The company’s earnings surprise history is mixed. It surpassed the consensus estimate in three of the last four quarters, while only missing on one occasion.

Among the 12 analysts covering WST stock, the consensus is a “Strong Buy.” That’s based on 11 “Strong Buy” ratings and one “Hold.”

The configuration is more bullish than three months ago, when only 10 analysts recommended a “Strong Buy.”

On Apr. 25, Evercore ISI analyst Daniel Markowitz maintained a “Buy” rating on West Pharmaceutical Services and announced a price target of $275.

WST’s mean price target of $284 indicates a premium of 38.1% from the current market prices. Its Street-high target of $355 suggests a robust 72.7% upside potential from current price levels.